ENLIVEN THERAPEUTICS, INC. (ELVN) /
The cash flow of ENLIVEN THERAPEUTICS, INC. over the past 7 years
Chart ENLIVEN THERAPEUTICS, INC.: operating cash flow, capital expenditures, free cash flow, fiscal 2019–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, ENLIVEN THERAPEUTICS, INC.'s operating cash flow was -$70.3M and its capital expenditures $158K, leaving free cash flow of -$70.46M. Free cash flow was below zero in all 7 years shown. It ranged from -$73.24M in fiscal 2024 to -$22.02M in fiscal 2019. Capital expenditures were highest in fiscal 2022, at $612K.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$70.3M | $158K | -$70.46M |
| 2024ended Dec 31, 2024 | -$73.19M | $44K | -$73.24M |
| 2023ended Dec 31, 2023 | -$61.27M | $149K | -$61.42M |
| 2022ended Dec 31, 2022 | -$32.08M | $612K | -$32.69M |
| 2021ended Dec 31, 2021 | -$46.77M | $12K | -$46.78M |
| 2020ended Dec 31, 2020 | -$37.4M | $18K | -$37.42M |
| 2019ended Dec 31, 2019 | -$21.88M | $140K | -$22.02M |
Fiscal years as ENLIVEN THERAPEUTICS, INC. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on ENLIVEN THERAPEUTICS, INC.
- The profitability of ENLIVEN THERAPEUTICS, INC.
- The debt of ENLIVEN THERAPEUTICS, INC.
- All of ENLIVEN THERAPEUTICS, INC.'s financials, charted
Companies of a similar size
- NBTBNBT BANCORP INC
- LGNLegence Corp.
- REZIResideo Technologies, Inc.
- BCCBoise Cascade Company
- HWKNHAWKINS, INC.
Not investment advice. This page shows what ENLIVEN THERAPEUTICS, INC. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.